Amgen sales and marketing update

Amgen expanded its First Step Program to include commercially insured patients. The program will help eligible patients in the U.S. outside of Massachusetts with their deductible, co-insurance or co-pay requirements for Neulasta pegfilgrastim, Nplate romiplostim, and Xgeva denosumab regardless of income. Patients will not be responsible for out-of-pocket costs for the first Nplate or Neulasta treatment associated with a new treatment regimen and will pay a maximum of $25 for subsequent injections. Maximum benefits per patient are $5,000 per six month period. ...